World TB Day: Rising Cases and Funding Cuts Threaten TB Control in L.A. County -

TB cases in Los Angeles County rose 3.4% year-over-year to 554 cases in 2025, the highest level since 2016, raising public health concerns. Officials warn that funding cuts risk reversing progress by increasing undetected, infectious cases and community spread; mitigation efforts in 2025 included over 4,200 nights of housing and more than 3,000 grocery/gas vouchers. Public Health launched the Southern California Regional Community of Practice to End TB to bolster provider capacity amid budget uncertainty.

Analysis

A low-rate uptick in a concentrated infectious disease often amplifies demand for diagnostic throughput and case-management services disproportionate to its headline magnitude. Expect procurement cycles for molecular platforms and cartridge consumables to be the first real revenue lever for public and private diagnostics vendors — orders can be lumpy and back-ended by 2–6 months as county programs run RFPs and labs validate assays.

Budget pressure at county and state levels is the principal near-term risk: if social support and housing-voucher programs are trimmed, hospital utilization and length-of-stay for complicated cases increase, shifting costs onto acute-care providers and insurers over a 3–12 month window. The larger, lower-probability macro tail is a rise in drug-resistant cases over multiple years, which would pivot demand from low-margin generics to higher-margin specialty antibiotics and diagnostic resistance-testing.

Market pricing today underweights two structural offsets: first, awareness campaigns and provider training typically increase case detection transiently, creating a detection spike that fades over 3–9 months as the marginal undiagnosed pool shrinks; second, federal/state grant windows (and private foundations) often backfill local cuts, meaning county-level budget bites are reversible within a legislative cycle. That makes option-based, catalyst-aware exposures preferable to outright leveraged directional bets.

Key Decisions for Investors

• Long DHR (Danaher) 9–12 month call or call spread (size 0.5–1.0% NAV). Rationale: exposure to molecular diagnostics/Cepheid platform demand from expanded public-health testing. Risk/reward: limited near-term revenue impact vs company scale (expect 10–20% upside if regional procurement ramps); stop-loss at -8% or hedge with short-term puts costing <0.25% NAV.
• Long HCA (HCA Healthcare) 3–9 month stock position (size 1% NAV) or buy-write to collect yield. Rationale: acute-care centers are first-line receivers of untreated/complicated cases if community support falls. Risk/reward: asymmetric payoff if hospital utilization rises (target +12–18%); cap downside with a 10% stop or protective 3–6 month puts.
• Small tactical long TEVA (Teva) 6–12 months (size 0.5% NAV) to capture any sustained rise in generic TB regimen demand. Rationale: generics producers benefit from volume and have defensive cashflow; low-margin but steady. Risk/reward: modest upside (5–15%) vs tail risk of drug-resistance requiring specialty drugs; keep position size small and exit if policy response restores community treatment subsidies.